Frankfurt
13.07.26 | 08:03
0,123 Euro
+1,15 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB | 303 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 30, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB held its Annual General Meeting today, Tuesday 30 June 2026, at Biotech center in... ► Artikel lesen | |
| 29.06. | IRLAB Therapeutics AB: IRLAB's rights issue was oversubscribed and the company resolves on allotment in the overallotment issue | 100 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
| 16.06. | IRLAB Therapeutics: IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies | 292 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 16, 2026 / IRLAB Therapeutics AB ((STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that... ► Artikel lesen | |
| IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Listing of subscription rights and paid subscription shares of IRLAB Therapeutics AB | 195 | GlobeNewswire | With effect from June 11, 2026, the subscription rights of IRLAB Therapeutics AB will be traded on the list for Equity rights. Trading will continue up until and including June 22, 2026.
... ► Artikel lesen | |
| 05.06. | Report from the Extraordinary General Meeting of IRLAB Therapeutics AB | 317 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 5, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB held its Extraordinary General Meeting today, Friday, 5 June 2026.The following main... ► Artikel lesen | |
| 05.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 05.06.2026 | 622 | Xetra Newsboard | Das Instrument 6IRA SE0012675361 IRLAB THERAP. AB A EQUITY wird cum Kapitalmassnahme gehandelt am 05.06.2026 und ex Kapitalmassnahme am 08.06.2026 The instrument 6IRA SE0012675361 IRLAB THERAP. AB A... ► Artikel lesen | |
| 03.06. | IRLAB Therapeutics: IRLAB Participates at Aktiedagarna in Stockholm on June 9 | 306 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 3, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announces that CEO Kristina... ► Artikel lesen | |
| 06.05. | IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - March 2026 | 417 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 6, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the... ► Artikel lesen | |
| 30.04. | IRLAB Therapeutics: Invitation to the Interim Report for Q1 2026 Presentation and Webcast | 369 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 30, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments... ► Artikel lesen | |
| 29.04. | IRLAB Therapeutics: IRLAB publishes the Annual Report for 2025 | 348 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announced today that... ► Artikel lesen | |
| 17.04. | Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026 | 449 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 09.04. | IRLAB Therapeutics: IRLAB to Present at Redeye Healthcare Day 2026 | 371 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 17.03. | IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at The AD/PD 2026 - 20th International Conference on Alzheimer's & Parkinson's Diseases | 401 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 02.03. | IRLAB Therapeutics: IRLAB Participates in Life Science Day in Gothenburg on March 4, 2026 | 307 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 2, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the... ► Artikel lesen | |
| 26.02. | IRLAB Therapeutics: IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease | 382 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA)... ► Artikel lesen | |
| 25.02. | IRLAB Therapeutics: IRLAB Publishes Full-Year Report for The Period January - December 2025 | 474 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 25, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 20.02. | IRLAB Therapeutics: IRLAB has Received Scientific Advisory Board Confirmation on Next Steps for Pirepemat | 389 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 18.02. | IRLAB Therapeutics: IRLAB: Invitation to the Year-End Report 2025 Presentation and Webcast | 298 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 18, 2026 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 19.01. | IRLAB Therapeutics: IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process | 381 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / January 19, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA),... ► Artikel lesen | |
| 23.12.25 | IRLAB Therapeutics: IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease | 485 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / December 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,12 | -1,14 % | Märkte am Morgen: Bayer, Deutsche Bank, SAP, Delivery Hero, Easyjet, ASML | Der DAX hat in der vergangenen Woche abgeliefert. Ein Plus von 4,5 Prozent bedeutet die beste Handelswoche seit April 2025. Vor allem an den letzten Tagen blies der DAX zur Rekordjagd, stellte eine... ► Artikel lesen | |
| MERCK KGAA | 139,35 | -0,18 % | Aktien Frankfurt Ausblick: Dax kaum bewegt nach Rekord | FRANKFURT (dpa-AFX) - Nach seinem Rekordlauf in der vergangenen Woche dürfte der Dax am Montag seine Gewinne halten. Stützend wirken teils freundliche Aktienmärkte in Asien. Dort sorge die Aussicht... ► Artikel lesen | |
| NOVO NORDISK | 43,280 | -0,22 % | Novo Nordisk: Kursziel rauf | Stück für Stück arbeitet sich die Aktie von Novo Nordisk aus dem Tal der Tränen. Zum Start in die neue Handelswoche verbucht das Papier des dänischen Biopharma-Konzerns an der Heimatbörse in Kopenhagen... ► Artikel lesen | |
| PMGC | 1,110 | -0,89 % | PMGC Holdings Inc.: NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression | Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,540 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,84 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| KARDIGAN | 24,550 | -0,34 % | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | ||
| PFIZER | 21,210 | +0,07 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Pfizer von 30 auf 28 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Seine Schätzungen für die Quartalszahlen am... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 36,720 | +0,30 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 38,6 USD | ||
| LB PHARMACEUTICALS | 32,950 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ||
| ELI LILLY | 1.038,60 | -0,23 % | Megatrend Folger: Eli Lilly sprengt die Billionen-Marke | Eli Lilly marschiert weiter an der Spitze des globalen Gesundheitssektors. Die Aktie des US-Pharmagiganten kletterte am Dienstag auf ein neues Allzeithoch und lässt damit die Marke von einer Billion... ► Artikel lesen | |
| CHINA PHARMA HOLDINGS | 0,635 | 0,00 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| SCHOTT PHARMA | 20,750 | +3,75 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Schott Pharma von 16 auf 22 Euro angehoben und die Aktien von "Hold" auf "Buy" hochgestuft. Der Spezialist für Verpackung und... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,642 | +0,66 % | VYNE Therapeutics Inc.: VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience | NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash... ► Artikel lesen | |
| ASTRAZENECA | 148,60 | -1,16 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18600 auf 18900 Pence angehoben und die Einstufung auf "Outperform" belassen. Vielversprechende... ► Artikel lesen |
IRLAB THERAPEUTICS AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,15 % bei einem Aktienkurs von 0,123 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IRLAB THERAPEUTICS AB finden Sie auf Wallstreet Online.